Article
A multimodal approach of microglial CSF1R inhibition and GENUS provides therapeutic effects in Alzheimer’s disease mice
2025-04-28
Abstract excerpt
<h4>Summary</h4> The CSF1R inhibitor PLX3397, an FDA-approved treatment for a rare cancer, has been shown to reduce microglia count, lower inflammation, and increase synaptic markers in mouse models of Alzheimer’s disease (AD). However, the effects of PLX3397 on neural function in AD remain largely unknown. Here, we characterized the effects of PLX3397 treatment in 5xFAD mice. While PLX3397 increased synaptic den...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 89de91fa-f2b9-58e3-8f42-2a6645c022ae
- DOI
- 10.1101/2025.04.27.648471
